A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity



Status:Completed
Conditions:Obesity Weight Loss, Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 65
Updated:4/2/2016
Start Date:December 2007
End Date:April 2015
Contact:Monique Gagnon, B.A.
Email:monique.gagnon@va.gov
Phone:858-552-8585

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver

Many metabolic complications of obesity are a consequence of abnormal responses of the
liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin,
preventing metabolic complications.


Inclusion Criteria:

- BMI >30

Exclusion Criteria:

- Diabetes Requiring Medication

- Poorly Controlled Co-Morbidities
We found this trial at
1
site
University of California at San Diego Hospitals
San Diego, California 92161
?
mi
from
San Diego, CA
Click here to add this to my saved trials